Feb 15, 2024 / 01:00PM GMT
Operator
Good morning. My name is Drew. I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines fourth quarter and full year 2023 financial results conference call. (Operator Instructions) Thank you.
Jenna Cohen, you may begin your conference.
Jenna Cohen - Blueprint Medicines Corp - Senior Director & Head of IR
Thank you, Drew. Good morning, everyone. Welcome to Blueprint Medicines fourth quarter and full year 2023 financial and operating results conference call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as slides that will be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.
Joining me are Kate Haviland, Chief Executive Officer; Philina Lee, Chief Commercial Officer; Fouad Namouni, President, Research & Development; Mike Landsittel, Chief Financial Officer; Christina Ross,
Q4 2023 Blueprint Medicines Corp Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot